FDA restrictions on e-cigarettes an important step to protect the health of youth
The University of Texas MD Anderson Cancer Center applauds new actions announced today by the U.S. Food and Drug Administration (FDA) to limit the sale of most flavored electronic cigarettes (e-cigarettes) to age-restricted locations and require age-verification for online sales to lower the use of these products in children. In addition, the FDA plans to restrict the marketing of these products toward youth.
“Today's actions by...
Fecal transplant effective against immunotherapy-induced colitis
For the first time, transplanting gut bacteria from healthy donors was used to successfully treat patients suffering from severe colitis caused...
Combination chemotherapy and immunotherapy effective in Phase II leukemia study
A combination of the standard-of-care chemotherapy drug known as azacitidine, with nivolumab, an immune checkpoint inhibitor, demonstrated...
MD Anderson fundraiser to honor James A. Baker, III
A Conversation With a Living Legend®, an annual luncheon benefiting The University of Texas MD Anderson Cancer Center, will pay tribute to the Honorable James A. Baker, III, the 61st U.S. secretary of state, 11:30 a.m.-1:30 p.m. Oct. 31 at the Marriott Rivercenter, 101 Bowie St.
Co-chairs Mary and Bob Worth and their children and their spouses, Clint and Jessica Worth, and Jordan and Brian Arriaga, of San Antonio, plan a dynamic...
Neoadjuvant combination checkpoint blockade trial yields high response rates for patients with high-risk stage 3 melanoma
Combination checkpoint blockade before surgery (neoadjuvant therapy) produced a high response rate among patients with high-risk stage 3 melanoma...
Press Event: MD Anderson immunologist Jim Allison awarded Nobel Prize
Jim Allison, Ph.D., chair of Immunology and executive director of the immunotherapy platform at The University of Texas...
Vaccine, anti-PD1 drug show promise against incurable HPV-related cancers
A tumor-specific vaccine combined with an immune checkpoint inhibitor shrank tumors in one third of patients with incurable cancer related...
MD Anderson hosts Biden Cancer Community Summit
The University of Texas MD Anderson Cancer Center today joined with more than 450 communities and institutions across the country in hosting...
MD Anderson immunotherapy expert Sharma wins Coley Award
Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology and Immunology at The University of Texas MD Anderson...
Study links BAP1 protein to tumor suppression in kidney, eye, bile duct and mesothelioma cancers
Researchers at The University of Texas MD Anderson Cancer Center have shown how BRCA-associated protein 1 (BAP1) serves as a tumor suppressor...
$50 million awarded by CPRIT to MD Anderson and its projects
The University of Texas MD Anderson Cancer Center today was awarded $30 million to support research, core facilities, recruitment and prevention...
MD Anderson and Accelerator Life Science Partners launch Magnolia Neurosciences to speed development of neuroprotective therapies
The University of Texas MD Anderson Cancer Center and Accelerator Life Science Partners, a leading life science investment and management...
Mendelsohn shares Tang Prize for leadership in developing targeted therapy
Targeted cancer therapy pioneer John Mendelsohn, M.D., researcher and former president of The University of Texas MD Anderson Cancer Center...
MD Anderson Therapeutics Discovery team identifies and advances a drug that targets metabolic vulnerability and impairs cancer cell growth and survival
A drug discovered and advanced by The University of Texas MD Anderson Cancer Center’s Institute for Applied Cancer Science (IACS) and TRACTION...
Checkpoint inhibitor shrinks advanced squamous cell skin cancer
Clinical trials show that an immune checkpoint inhibitor shrinks the tumors of nearly half of patients with an incurable, advanced form of...
New approach to cancer research aims to accelerate studies and reduce cost
A new model for improving how clinical trials are developed and conducted by bringing together academic cancer experts and pharmaceutical...
Preclinical MD Anderson study suggests ARID1a may be useful biomarker for immunotherapy
Functional loss of ARID1a, a frequently mutated tumor suppressor gene, causes deficiencies in normal DNA repair and may sensitize tumors to...
MD Anderson, Spectrum Pharmaceuticals complete poziotinib licensing deal
The University of Texas MD Anderson Cancer Center and Spectrum Pharmaceuticals have signed a licensing agreement that covers discoveries by...
Precancerous colon polyps in patients with Lynch syndrome exhibit immune activation
Colon polyps from patients with Lynch syndrome, a hereditary condition that raises colorectal cancer risk, display immune system activation...
Future MD Anderson Location in The Woodlands® Tops Out
The University of Texas MD Anderson Cancer Center today celebrated a milestone in the construction of its three-story clinic in The Woodlands...
MD Anderson and RaySearch announce strategic alliance to advance radiation therapy of cancer
The University of Texas MD Anderson Cancer Center and RaySearch Laboratories today announced a strategic alliance with the aim of enhancing...
MD Anderson receives $22 million in CPRIT funding for research, prevention and recruitment
The University of Texas MD Anderson Cancer Center was awarded $22.3 million from the Cancer Prevention and Research Institute of Texas...
Presurgical targeted therapy delays relapse of high-risk stage 3 melanoma
A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared...
National Academy of Sciences awards Kovalenko medal to immunotherapy pioneer Allison
Cancer immunotherapy innovator Jim Allison, Ph.D., chair of Immunology at The University of Texas MD Anderson Cancer Center, will receive...
MD Anderson and UT Health San Antonio applaud San Antonio City Council for increasing tobacco sale age to 21
The University of Texas MD Anderson Cancer Center and UT Health San Antonio applaud the actions of the San Antonio City Council today in voting...
MD Anderson experts to share latest in cancer treatment, research
Leaders of The University of Texas MD Anderson Cancer Center will head to Palm Beach Jan. 22 to present innovations in cancer research, treatment...
New cancer model shows genomic link between early-stage and invasive breast cancer types
A new genetic-based model may explain how a common form of early-stage breast cancer known as ductal carcinoma in situ (DCIS) progresses to...